Shira Naomi Dinner

Associate Professor, Medicine, Hematology Oncology Division

Emailshira.dinner@northwestern.edu

Source: Scopus

Research activity per year

If you made any changes in Pure these will be visible here soon.

Personal profile

Certifications and Licenses

	Internal Medicine
	Hematology & Oncology

Training Experience

2010	Residency, University of Chicago
2013	Fellowship, Stanford University Hospitals

Education/Academic qualification

Medicine, MD, University of Chicago

… → 2007

Fingerprint

Dive into the research topics where Shira Naomi Dinner is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

12 Similar Profiles

Network

Recent external collaboration on country level. Dive into details by clicking on the dots.

10 Finished
12 Active

Prot #UCART123_01: Phase I, Open Label Dose Escalation and Dose-Expansion Study to Evaluate the Safety, Expansion, Persistence and Clinical Activity of UCART123 (Allogeneic Engineered T-cells Expressing Anti-CD123 Chimeric Antigen Receptor), Administered
Dinner, S. N.
Cellectis S.A.
11/10/20 → 11/10/23
Project: Research project
Prot #5F9009: ENHANCE: A Randomized, Double-blind, Multicenter Study Comparing Magrolimab in Combination with Azacitidine versus Azacitidine Plus Placebo in Treatment-naïve Patients with Higher Risk Myelodysplastic Syndrome
Dinner, S. N.
ICON Clinical Research, LLC, Forty Seven, Inc.
8/18/20 → 8/18/23
Project: Research project
Prot #CMBG453B12301: A Randomized, Double-Blind, Placebo-Controlled Phase III Multi-Center Study of Azacitidine With or Without MBG453 for the Treatment of Patients With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as per IPSS-R, or
Dinner, S. N.
Novartis Pharmaceuticals Corporation
6/25/20 → 7/31/28
Project: Research project
Prot #NU 19H05: Phase 1 trial of Ivosidenib and FLAG Chemotherapy in Relapsed/Refractory IDH1+ Acute Myeloid Leukemia (AML)
Dinner, S. N.
Agios Pharmaceuticals, Inc.
2/5/20 → 12/15/23
Project: Research project
Supportive Oncology Collaborative for Adolescents and Young Adults
Garcia, S. F., Sanford, S. D., Dinner, S. N. & Kircher, S. M.
Coleman Foundation, Inc.
1/1/20 → 6/30/21
Project: Research project

475 Citations
20 Article
6 Review article
1 Chapter
1 Short survey

Sequencing of novel agents in relapsed/refractory B-cell acute lymphoblastic leukemia: Blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or second novel agent therapy in relapsed/refractory acute lymphoblastic leukemia
Badar, T., Szabo, A., Dinner, S., Liedtke, M., Burkart, M., Shallis, R. M., Yurkiewicz, I. R., Kuo, E., Khan, M. A., Balasubramanian, S., Yang, J., Hefazi, M., Podoltsev, N., Patel, A., Curran, E., Wang, A., Arslan, S., Aldoss, I., Siebenaller, C., Mattison, R. J. & 4 others, Litzow, M. R., Wadleigh, M., Advani, A. S. & Atallah, E., Apr 1 2021, In: Cancer. 127, 7, p. 1039-1048 10 p.
Research output: Contribution to journal › Article › peer-review
Hematopoietic growth factors, version 1.2020: Featured updates to the NCCN guidelines
Becker, P. S., Griffiths, E. A., Alwan, L. M., Bachiashvili, K., Brown, A., Cool, R., Curtin, P., Dinner, S., Gojo, I., Hicks, A., Kallam, A., Kidwai, W. Z., Kloth, D. D., Kraut, E. H., Landsburg, D., Lyman, G. H., Miller, R., Mukherjee, S., Patel, S., Perez, L. E. & 13 others, Poust, A., Rampal, R., Rosovsky, R., Roy, V., Rugo, H. S., Shayani, S., Vasu, S., Wadleigh, M., Westbrook, K., Westervelt, P., Burns, J., Keller, J. & Pluchino, L. A., 2020, In: JNCCN Journal of the National Comprehensive Cancer Network. 18, 1, p. 12-22 11 p.
Research output: Contribution to journal › Article › peer-review

Open Access
13 Scopus citations
Real-world outcomes of adult B-cell acute lymphocytic leukemia patients treated with blinatumomab
Badar, T., Szabo, A., Advani, A., Wadleigh, M., Arslan, S., Khan, M. A., Aldoss, I., Siebenaller, C., Schultz, E., Hefazi, M., Shallis, R. M., Yurkiewicz, I., Podoltsev, N., Patel, A. A., Curran, E., Balasubramanian, S., Yang, J., Mattison, R. J., Burkart, M., Dinner, S. & 3 others, Liedtke, M., Litzow, M. R. & Atallah, E., May 26 2020, In: Blood Advances. 4, 10, p. 2308-2316 9 p.
Research output: Contribution to journal › Article › peer-review

Open Access
2 Scopus citations
Real-World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated With Inotuzumab Ozogamicin
Badar, T., Szabo, A., Wadleigh, M., Liedtke, M., Arslan, S., Siebenaller, C., Aldoss, I., Schultz, E., Hefazi, M., Litzow, M. R., Kuo, E., Wang, A., Curran, E., Shallis, R. M., Podoltsev, N., Balasubramanian, S., Yang, J., Mattison, R., Burkart, M., Dinner, S. & 2 others, Advani, A. & Atallah, E., Aug 2020, In: Clinical Lymphoma, Myeloma and Leukemia. 20, 8, p. 556-560.e2
Research output: Contribution to journal › Article › peer-review
4 Scopus citations
Therapy-related B-cell acute lymphoblastic leukemia in adults has unique genetic profile with frequent loss of TP53 and inferior outcome
Barnea Slonim, L., Gao, J., Burkart, M., Odetola, O. E., Kocherginsky, M., Dinner, S. N., Lu, X., Wehbe, F., Jennings, L., Altman, J. K., Mirza, K. M., Chen, Y. H. & Sukhanova, M., 2020, (Accepted/In press) In: Leukemia.
Research output: Contribution to journal › Article › peer-review